SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is experiencing sustained momentum driven by a growing community focused on celebrating cannabis culture and the plant's medicinal potential. Enthusiasts are actively coordinating to build a long-term presence on-chain, emphasizing the project's steady progress and the anticipation surrounding the annual 4/20 cultural milestones.

Bakkt, Inc. is building the backbone of next-generation financial infrastructure. The company provides solutions that enable institutional participation in the digital asset economy, spanning Bitcoin, tokenization, stablecoin payments, and AI-driven finance. Bakkt was founded in 2018 and is headquartered in New York, NY.

Bakkt Inc. - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is drawing significant attention as investors react to a strategic acquisition and persistent rumors of potential partnerships, with community sentiment fueled by the stock's high volatility and strong correlation to Bitcoin's price action. While some traders are focused on a potential short squeeze or a broader institutional re-rating, others remain cautious, debating the long-term impact of share dilution and the company's ability to execute on its pivot toward stablecoin settlement and institutional infrastructure.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoin is experiencing intense community focus as traders speculate on its potential for human identity verification and its role in an increasingly AI-driven digital economy. The conversation is heavily centered on its utility as a 'Proof of Personhood' solution and the impact of recent treasury initiatives and institutional interest surrounding the project.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is gaining significant momentum as investors pivot toward its long-term potential as an AI and energy-infrastructure company rather than just an EV manufacturer. The community is actively discussing the company's recent expansion of its battery-swapping network and its strategic move into self-developed AI chips, with many looking toward upcoming vehicle delivery milestones as a key catalyst to drive the share price through current resistance levels.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending amid intense market volatility driven by regional conflict in the Middle East and concerns over the stability of the Strait of Hormuz. The community is actively debating the impact of potential supply disruptions against the backdrop of broader economic uncertainty, with traders sharply divided between bullish expectations for continued energy price spikes and bearish concerns regarding aggressive market manipulation and speculative bubbles.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is gaining significant traction as a key infrastructure provider in the DeFi space, with community sentiment fueled by its role in the Real World Asset (RWA) narrative and its integration of institutional-grade financial data. Investors are actively discussing the protocol's revenue-sharing model through token buybacks and its unique utility in supplying government-validated macroeconomic data to blockchain ecosystems.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

The SPDR Dow Jones Industrial Average ETF (DIA) is trending as the broader market grapples with extreme volatility driven by the escalating conflict in Iran, which has sparked fears over oil supply and global shipping routes. Investors are closely monitoring erratic signals from the Trump administration regarding the conflict and energy supply, while debating the long-term economic impacts of rising inflation and geopolitical instability.

Vanguard Malvern Funds - Vanguard Short-Term Inflation-Protected Securities Index Fund

Vanguard Short-Term Inflation-Protected Securities ETF

VTIP is currently trending as investors seek protection against rising inflation, with market participants actively debating the effectiveness of short-term TIPS ETFs as a hedge against economic volatility. Community discussions center on the interplay between persistent inflationary pressures and the broader bond market, as investors look for ways to safeguard purchasing power amidst shifting economic conditions.

FIS Trust - FIS Christian Stock Shares of beneficial interest

SHP ETF Trust - FIS Biblically Responsible Risk Managed ETF

Investors are actively debating the intersection of personal faith and portfolio management, with many sharing scripture and reflections on ethical investing within the PRAY ETF community. While some participants are discussing the fund's alignment with their values, others are using the platform as a space to share personal motivations for market participation and conservative lifestyle principles.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is trending as investors aggressively hedge against heightened geopolitical risks, including escalating tensions with Iran and uncertainty surrounding new trade tariff policies. The community is actively debating the volatility ETF's structural decay, with many traders using it as a tactical tool to capitalize on daily market swings and anticipated macro-economic shocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of BrainStorm Cell Therapeutics slipped in after-hours trading Thursday after the company said&nbsp;it has been removed from the Nasdaq Capital Market for falling short of minimum equity requirements.The stock will stop trading on Nasdaq when&nbsp;the&nbsp;markets open Friday.&nbsp;Brainstorm Cell’s stock plunged 42.7% in after-hours trading on Thursday, falling to $0.67, following a 2.5% dip during the regular session.The company said it has received approval to shift its listing to the OTCQB Venture Market, where it will continue trading under the same ticker.“While this delisting is a difficult outcome, it does not change our core mission or our dedication to the ALS community,” said CEO Chaim Lebovits. “Our move to the OTCQB ensures trading continuity and allows us to maintain focus on advancing NurOwn.”NurOwn is BrainStorm’s experimental cell therapy for ALS, a progressive disease that steadily weakens muscles and shortens lives.&nbsp;The company is preparing to launch a pivotal Phase 3b trial, designed in coordination with the FDA under a Special Protocol Assessment agreement.In June, BrainStorm released new survival data from 10 ALS patients who received NurOwn through its Expanded Access Program.The company reported that 90% of those patients survived more than five years from symptom onset, marking a significant contrast to the roughly 10% survival rate reported in the general ALS population.&nbsp;The median survival was 6.8 years, with the only death attributed to elective euthanasia.To support the upcoming trial, BrainStorm recently entered a manufacturing agreement with Minaris Advanced Therapies, a U.S.-based contract development and manufacturing organization.&nbsp;It has also partnered with Israel-based Pluri to expand clinical supply capabilities.The company stated that the Nasdaq delisting will not affect its business operations, R&amp;D activities, or its commitment to shareholders.On Stocktwits, retail sentiment for Brainstorm was ‘bullish’ amid ‘high’ message volume.One user said that BrainStorm can possibly tap the at-the-market (ATM) facility to fund its upcoming trial, citing the stock’s rebound.<stembedurl>https://stocktwits.com/steven_glandsberg/message/621369650</stembedurl>Another user saw the dip as a buying opportunity, calling it a “good buy time.”<stembedurl>https://stocktwits.com/bigdave100/message/621361783</stembedurl><a href="https://stocktwits.com/symbol/BCLI">Brainstorm’s stock</a> has declined 45.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a man walking in front of the Nasdaq building at Times Square in New York. (Photo by John Smith/VIEWpress)

BrainStorm Cell Therapeutics Crashes After Hours On Nasdaq Delisting Notice; Retail Sees 'Buy Time'

Shares of BrainStorm Cell Therapeutics slipped in after-hours trading Thursday after the company said it has been removed from the Nasdaq Capital Market for falling short of minimum equity requirements.

Equity

The company plans to move its shares to the OTCQB market and says the delisting won't impact its ALS research or upcoming Phase 3b trial. 

BrainStorm Cell Therapeutics saw rising retail chatter Monday when it obtained FDA clearance for Phase 3b clinical trials of NurOwn, its amyotrophic lateral sclerosis (ALS) stem cell therapy candidate.Through a Special Protocol Assessment (SPA), the FDA confirmed that the study design and statistical methodology meet regulatory standards required for future BLAs.The company’s shares closed up 3.03% at $1.36 on Monday but slipped 12.54% to $1.19 in after-hours trading.BrainStorm CEO Chaim Lebovits said the FDA approval allows the company to commence operations at clinical sites while it pursues funding through multiple sources, such as non-dilutive grants.The clinical Phase 3b trial aims to enroll around 200 ALS patients from leading academic institutions.&nbsp;A 24-week double-blind placebo-controlled trial will initiate the study before moving into a 24-week open-label extension, during which all patients receive NurOwn.&nbsp;Researchers will assess the primary outcome by measuring the change in ALSFRS-R scores from baseline to week 24.Completing Phase 3 research allows NurOwn to hold Orphan Drug status concurrently in the United States and the European Union.&nbsp;Meanwhile, the U.S. Patent Office approved BrainStorm's intellectual property rights to develop an allogeneic exosome-based platform.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 31,000% surge in 24-hour message volume.Some traders pointed to the company’s pursuit of private grants or potential partnerships, with names like Johns Hopkins University and Pfizer mentioned as speculative collaborators, as key bullish drivers.<stembedurl>https://stocktwits.com/Whealthy/message/615149075</stembedurl>Others noted the heavy intraday volume, which reached 58 million shares, expressing frustration over the lack of price movement during regular hours.&nbsp;Still, optimism remained for a possible after-hours push or improved action in the following session, with hopes for reduced resistance ahead.<stembedurl>https://stocktwits.com/Kojak3/message/615151221</stembedurl>The stock has declined 36.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Physical Therapy for the Elderly Caused by Amyotrophic Lateral Sclerosis. Asian home nurse helping a senior woman while doing physical therapy on her patient outdoors. Photo credit: Getty Images

Retail Bulls Cheer FDA Clearance For BrainStorm’s ALS Therapy, But Shares Dip After Hours

BrainStorm Cell Therapeutics plans to enroll 200 ALS patients in its FDA-cleared Phase 3b trial of NurOwn, with a 24-week double-blind phase followed by an open-label extension.

WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters.&nbsp;Our focus is on quality, liquid, growth-oriented, and under-followed companies in sectors actively drawing in capital such as AI, blockchain, biotech and consumer.&nbsp;This real-time news surveillance and targeting combined with our proprietary 5-point analysis, aids in uncovering stocks poised for powerful multi-day or multi-month moves—often long before Wall Street analysts catch on.&nbsp;Here’s what we’re keeping our eyes on:<h3>1. Purple Biotech (NASDAQ: PPBT)</h3>Background: Purple Biotech is a clinical-stage oncology company that aims to redefine cancer treatment through its innovative approaches targeting tumor immune evasion and drug resistance. Its lead product, CM24, is a first-in-class anti-CEACAM1 antibody being developed to treat pancreatic and other aggressive cancers. The oncology space, worth billions, continues to see intense investor interest, especially as companies explore biomarker-driven therapies.The News: Purple Biotech unveiled final Phase 2 results showing CM24 combined with nivolumab and chemotherapy significantly improved overall survival (OS) and progression-free survival (PFS) in pancreatic cancer patients with specific biomarkers. The data revealed a 79% reduction in death risk and a 5.1-month OS improvement, particularly in biomarker-enriched patient groups.What It Means: These results not only validate CM24’s potential but also position Purple Biotech to expand its pipeline into broader cancer applications. With a planned Phase 2b trial targeting high-CEACAM1 patients, the company is tapping into precision oncology—a sector that continues to draw investor enthusiasm due to its game-changing potential.Stock Reaction: PPBT skyrocketed 151%, reflecting the market’s recognition of this major milestone in the fight against pancreatic cancer.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_23_40_AM_19763a2e26.png" alt="Screenshot 2024-12-05 at 2.23.40 AM.png">&nbsp;<hr>&nbsp;<h3>2. Stereotaxis (NYSE: STXS)</h3>Background: Stereotaxis is at the forefront of surgical robotics, specializing in robotic magnetic navigation (RMN) systems for minimally invasive endovascular interventions. Its GenesisX system aims to improve precision, safety, and efficiency in procedures, a critical innovation as the global market for robotic-assisted surgeries is projected to grow at a double-digit CAGR over the next decade.The News: The GenesisX robotic system was showcased for the first time at the RSNA 2024 Annual Meeting, in collaboration with Neusoft Medical Systems. The partnership aligns GenesisX with advanced imaging technologies, offering enhanced capabilities for healthcare providers worldwide.What It Means: The exposure at RSNA, one of the largest radiology conferences globally, strengthens Stereotaxis' visibility and positions the GenesisX as a next-generation tool for minimally invasive surgeries. This partnership could unlock new revenue streams as the healthcare sector increasingly adopts robotic solutions.Stock Reaction: STXS edged up 4.18%, with investors optimistic about the long-term implications of the GenesisX system.Stocktwits.com Sentiment &amp; Popularity:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_25_09_AM_6fecf5b145.png" alt="Screenshot 2024-12-05 at 2.25.09 AM.png">&nbsp;<hr>&nbsp;<h3>3. Delcath Systems (NASDAQ: DCTH)</h3>Background: Delcath Systems focuses on innovative therapies for primary and metastatic liver cancers. Its flagship product, HEPZATO KIT™, offers a unique approach to delivering high-dose chemotherapy directly to the liver while minimizing systemic exposure. This precision is critical for targeting liver-dominant diseases—a market that represents tens of thousands of patients annually.The News: The FDA has cleared Delcath’s Phase 2 trial of HEPZATO in liver-dominant metastatic colorectal cancer. The study will compare HEPZATO plus standard chemotherapy with chemotherapy alone, aiming to validate its safety and efficacy in this high-need population.What It Means: HEPZATO has already shown promise in metastatic uveal melanoma, and this expansion could significantly broaden its market reach. The ability to address liver-dominant cancers positions Delcath as a potential leader in a niche but high-value market.Stock Reaction: DCTH rose 6.4% on the day, continuing its strong performance following a 203% year-to-date rally.&nbsp;&nbsp;<hr>&nbsp;<h3>4. BrainStorm Cell Therapeutics (NASDAQ: BCLI)</h3>Background: BrainStorm is a pioneering biotech company developing autologous adult stem cell therapies for neurodegenerative diseases like ALS and progressive MS. Its lead candidate, NurOwn®, is designed to deliver neurotrophic factors directly to damaged neurons, potentially altering the course of these debilitating diseases. With few effective therapies for ALS, the market is ripe for disruptive innovation.The News: BrainStorm announced a December 11 webinar featuring updates on its Phase 3b trial of NurOwn, aimed at refining the therapy’s efficacy for FDA approval. This comes as the company prepares for a pivotal registrational trial.What It Means: If successful, NurOwn could be the first significant breakthrough for ALS in years, addressing an unmet medical need in a multibillion-dollar market. The company’s focus on early-stage ALS patients may improve trial outcomes and strengthen its case for regulatory approval.Stock Reaction: BCLI dipped 2.66%, reflecting cautious investor sentiment as the market awaits trial data.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_26_15_AM_28681ca8de.png" alt="Screenshot 2024-12-05 at 2.26.15 AM.png">&nbsp;<hr>&nbsp;<h3>5. DMG Blockchain Solutions (OTCQB: DMGGF)</h3>Background: DMG Blockchain integrates Bitcoin mining with sustainability and AI-driven data centers. Its Terra Pool initiative is designed to create a carbon-neutral Bitcoin mining ecosystem, catering to ESG-conscious investors and industries. With institutional adoption of Bitcoin accelerating, DMG’s dual focus on growth and environmental responsibility makes it a standout.The News: DMG reported November mining results of 32 BTC, an increased hashrate of 1.66 EH/s, and significant insider purchases by its CEO and COO. The company also secured $17.3 million to fund growth initiatives, including AI and blockchain infrastructure.What It Means: The raised capital and insider purchases signal confidence in DMG’s ability to scale operations and align with Bitcoin’s anticipated market growth. The focus on sustainability could attract institutional players prioritizing ESG compliance.Stock Reaction: DMGI remained stable dipping just slightly, with the market digesting the long-term growth potential from recent investments.&nbsp;<hr>&nbsp;<h3>6. BriaCell Therapeutics (NASDAQ: BCTX)</h3>Background: BriaCell specializes in novel immunotherapies targeting advanced breast cancer. Its lead therapy, Bria-IMT™, is designed to boost the immune system's response against tumors. With metastatic breast cancer affecting over 2 million women globally, there’s an urgent need for effective treatments.The News: BriaCell’s pivotal Phase 3 study of Bria-IMT received a positive safety review from the DSMB, allowing the trial to proceed without changes. The trial is being conducted under the FDA’s Fast Track Designation.What It Means: The DSMB’s approval reinforces Bria-IMT’s safety and paves the way for the company to potentially deliver a game-changing therapy for metastatic breast cancer patients. The Fast Track Designation further emphasizes its potential impact.Stock Reaction: BCTX shares soared 13%, reflecting growing investor confidence in the company’s clinical progress.Rumours from Twitter:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_27_31_AM_e685b0a306.png" alt="Screenshot 2024-12-05 at 2.27.31 AM.png">&nbsp;&nbsp;<h3>7. Laser Photonics Corporation (NASDAQ: LASE)</h3>Background: Laser Photonics Corporation specializes in industrial laser systems, providing innovative solutions for cleaning, material processing, and now pharmaceuticals. With its recent acquisition of Control Micro Systems, Inc., the company is expanding into new sectors, including the fast-growing pharmaceutical and semiconductor industries. The industrial laser market, driven by advances in automation and precision engineering, is projected to exceed $10 billion by 2030, making it a hotbed for innovation.The News: Laser Photonics announced the successful installation of a state-of-the-art pill drilling system at a customer’s facility. The system, a Class I automated CO2 laser with advanced fume extraction and machine vision inspection, is designed to streamline pill production processes. This system also doubles as an anti-counterfeiting solution, addressing critical challenges in the pharmaceutical supply chain.What It Means: This installation signifies Laser Photonics’ pivot into high-demand verticals like pharmaceuticals. By integrating advanced laser technology with automated inspection, the company is positioning itself as a key supplier in a market prioritizing efficiency, precision, and security.Stock Reaction: LASE shares declined 6.40%, reflecting broader market volatility rather than company-specific concerns. Investors appear cautiously optimistic about the company's potential in its newly targeted markets.&nbsp;Also Read:<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/featured/why-this-small-biotech-stock-could-be-primed-for-a-breakout/">&nbsp;Why This Small Biotech Stock Could Be Primed for a Breakout</a>Be the First to Know:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like&nbsp;AST SpaceMobile (NASDAQ: ASTS), which shot up&nbsp;+533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a long or short position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

News Movers: Yesterday’s Hottest News That Could Move the Needle Today

Your Only Digest of Market-Moving News and Rumours From High-Growth, Small Cap Stocks

Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.28	--	--	N/A
Q3 '25	-$0.37	-$0.19	48.65%	BEAT
Q2 '25	-$0.37	-$0.34	8.11%	BEAT
Q1 '25	-$0.97	-$0.45	53.61%	BEAT
Q4 '24	-$0.38	--	--	N/A

BCLI
Brainstorm Cell Therapeutics, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest BCLI News

BCLIBrainstorm Cell Therapeutics, Inc.